AVROBIO, Inc. (NASDAQ:AVRO) Receives $7.84 Average Price Target from Analysts

Shares of AVROBIO, Inc. (NASDAQ:AVROGet Rating) have earned an average recommendation of “Buy” from the nine brokerages that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $7.84.

A number of equities analysts recently commented on AVRO shares. Barclays increased their price target on AVROBIO from $6.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, January 5th. Mizuho lowered their price objective on AVROBIO from $28.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, January 6th. Needham & Company LLC lowered their price objective on AVROBIO from $28.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 5th. Wells Fargo & Company lowered their price objective on AVROBIO from $36.00 to $8.00 and set an “overweight” rating for the company in a research note on Wednesday, January 5th. Finally, Stifel Europe lowered their price objective on AVROBIO from $9.00 to $4.00 in a research note on Tuesday, January 4th.

Shares of AVROBIO stock opened at $1.14 on Friday. The stock has a 50 day moving average of $1.49 and a 200 day moving average of $3.24. AVROBIO has a 12 month low of $1.13 and a 12 month high of $12.01. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.27 and a quick ratio of 10.27.

AVROBIO (NASDAQ:AVROGet Rating) last announced its quarterly earnings results on Thursday, March 17th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.09. As a group, analysts forecast that AVROBIO will post -2.02 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVRO. Point72 Hong Kong Ltd purchased a new position in AVROBIO during the 3rd quarter worth $26,000. BNP Paribas Arbitrage SA increased its holdings in AVROBIO by 112.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 9,665 shares of the company’s stock worth $54,000 after purchasing an additional 5,117 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in AVROBIO during the 3rd quarter worth $63,000. Marshall Wace LLP purchased a new position in AVROBIO during the 3rd quarter worth $63,000. Finally, Raymond James & Associates purchased a new position in AVROBIO during the 3rd quarter worth $85,000. Institutional investors own 67.18% of the company’s stock.

About AVROBIO (Get Rating)

AVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease.

Featured Stories

Analyst Recommendations for AVROBIO (NASDAQ:AVRO)

Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.